The Protective Barrier to Resistance of Darunavir in a Convenient STR1

Approximately 20% smaller than PREZCOBIX®

One tablet, once daily with food

SYMTUZA® Dosing and Drug Interactions

Drugs that are contraindicated

Alpha 1-adrenoreceptor agonist alfuzosin
Antianginal ranolazine
Antiarrhythmic dronedarone
Anticonvulsants carbamazepine, phenobarbital, phenytoin
Anti-gout colchicine in patients with renal or hepatic impairment
Antimycobacterial rifampin
Antipsychotic lurasidone, pimozide
Ergot derivatives dihydroergotamine, ergotamine, methylergonovine
GI motility agent cisapride
Herbal product St. John’s wort (Hypericum perforatum)
Hepatitis C direct-acting antiviral elbasvir/grazoprevir
HMG-CoA reductase inhibitors lovastatin, simvastatin
PDE-5 inhibitor sildenafil for treatment of pulmonary arterial hypertension
Sedative/hypnotic midazolam (oral), triazolam

Coadministration not recommended*

Anticoagulants rivaroxaban
Anticonvulsants eslicarbazepine, oxcarbazepine
Antifungals voriconazole
Antimycobacterials rifapentine, rifabutin
Systemic/inhaled/nasal/ophthalmic corticosteroids betamethasone, budesonide, ciclesonide, dexamethasone, fluticasone, methylprednisolone, mometasone, triamcinolone
Hepatitis C direct-acting antivirals simeprevir
Immunosuppressant/neoplastic everolimus
Inhaled beta agonist salmeterol
PDE-5 inhibitor avanafil
Platelet aggregation inhibitor ticagrelor

* Recommendations are based on drug interaction trials conducted with components of SYMTUZA®, as individual agents or in combination, or are predicted interactions.

GI=gastrointestinal; HMG-CoA=3-hydroxy-3-methyl-glutaryl-coenzyme A; PDE-5=phosphodiesterase type 5; STR=single-tablet regimen.

Reference: 1. SYMTUZA® [package insert]. Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP.